HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide  by Luznik, Leo et al.
Biology of Blood and Marrow Transplantation 14:641-650 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1406-0001$32.00/0
doi:10.1016/j.bbmt.2008.03.005HLA-Haploidentical Bone Marrow Transplantation for
Hematologic Malignancies Using Nonmyeloablative
Conditioning and High-Dose, Posttransplantation
Cyclophosphamide
Leo Luznik,1* Paul V. O’Donnell,2,3* Heather J. Symons,1 Allen R. Chen,1 M. Susan Leffell,1
Marianna Zahurak,1 Ted A. Gooley,2,3 Steve Piantadosi,1 Michele Kaup,1 Richard F. Ambinder,1
Carol Ann Huff,1 William Matsui,1 Javier Bolan˜os-Meade,1 Ivan Borrello,1 Jonathan D. Powell,1
Elizabeth Harrington,2 Sandy Warnock,2 Mary Flowers,2,3 Robert A. Brodsky,1 Brenda M. Sandmaier,2,3
Rainer F. Storb,2,3 Richard J. Jones,1 Ephraim J. Fuchs1
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; 2Fred Hutchinson Cancer
Research Center, Seattle, Washington; and 3University of Washington School of Medicine Seattle, Washington
Correspondence and reprint requests: Ephraim J. Fuchs, MD, 488 Bunting-Blaustein Cancer Research Building, 1650
Orleans Street, Baltimore, MD 21231. (e-mail: fuchsep@jhmi.edu).
*These authors contributed equally to this work.
Received November 17, 2007; accepted March 16, 2008
ABSTRACT
We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft
rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative conditioning and T cell-
replete bone marrow transplantation from partially HLA-mismatched (haploidentical) related donors. Patients
with advanced hematologic malignancies (n 5 67) or paroxysmal nocturnal hemoglobinuria (n 5 1) received Cy
50 mg/kg i.v. on day 3 (n5 28) or on days 3 and 4 (n5 40) after transplantation. The median times to neutrophil
(.500/mL) and platelet recovery (.20,000/mL)were 15 and 24 days, respectively. Graft failure occurred in 9 of 66
(13%) evaluable patients, and was fatal in 1. The cumulative incidences of grades II-IV and grades III-IV acute
(aGVHD) by day 200 were 34% and 6%, respectively. There was a trend toward a lower risk of extensive chronic
GVHD (cGVHD) among recipients of 2 versus 1 dose of posttransplantation Cy (P 5 .05), the only difference
between these groups. The cumulative incidences of nonrelapse mortality (NRM) and relapse at 1 year were
15% and 51%, respectively. Actuarial overall survival (OS) and event-free survival (EFS) at 2 years after trans-
plantation were 36% and 26%, respectively. Patients with lymphoid malignancies had an improved EFS com-
pared to those with myelogenous malignancies (P 5 .02). Nonmyeloablative HLA-haploidentical BMT with
posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD.
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Allogeneic blood or marrow transplantation
(alloBMT), following either marrow-ablative or non-
myeloablative conditioning, is a potentially curative
treatment for a variety of hematologic malignancies
and nonmalignant hematologic disorders [1]. Of all
the potential sources of allografts, those from humanleukocyte antigen (HLA)-matched siblings have gen-
erally produced the best overall and progression-free
survival (OS, PFS) [2]. Unfortunately, only about
a third of candidates for alloBMT have HLA-matched
siblings. For patients who lack HLA-matched siblings,
there are 3 alternative sources of stem cells for al-
loBMT: (1) volunteer unrelated donors, (2) umbilical641
642 L. Luznik et al.cord blood, and (3) partially HLA-mismatched, or
haploidentical, related donors [3]. Because any patient
shares exactly one HLA haplotype with each biologic
parent or child and half of siblings, an eligible HLA-
haploidentical donor can be identified rapidly in nearly
all cases. However, HLA-haploidentical BMT has
been associated with significant risks of graft rejection
and severe GVHD [4-6], which are manifestations of
excessive alloreactivity by host [7] and donor T cells
[8], respectively. The risk of severe GVHDmay be re-
duced in intensively conditioned recipients of grafts
that have been rigorously depleted of mature T cells
or selectively depleted of alloreactive T cells, but the
risks of serious infection and death from prolonged
immune compromise in these patients remain high
[9-14]. To reduce the toxicity of haploidentical
BMT, methods to selectively inhibit alloreactivity
while preserving immunity to infection and the malig-
nancy are clearly required [15].
Cyclophosphamide (Cy) is a highly immunosup-
pressive antineoplastic agent that has an established
role in conditioning for alloBMT. Typically, the
drug is administered prior to transplantation to pre-
vent graft rejection by suppressing the host immune
system. However, pretransplantation conditioning
with Cy increases the risk of GVHD following alloge-
neic T cell infusion in mouse models [16]. In contrast,
administration of a properly timed, high dose of Cy
after BMT inhibits both graft rejection and GVHD
[17-20]. In light of this observation, we conducted
a Phase I/II trial of high-dose, posttransplantation
Cy after nonmyeloablative conditioning and trans-
plantation of non-T cell-depleted, HLA-haploidenti-
cal marrow for patients with poor risk hematologic
malignancies and nonmalignant hematologic disor-
ders [21]. That trial demonstrated that partially
HLA-mismatched bone marrow can engraft rapidly
and stably after nonmyeloablative conditioning that
includes posttransplantation Cy. However, the
cumulative incidence of graft failure and severe
GVHD remained high, approaching 60% at 6 months
posttransplant.We now report on outcomes after non-
myeloablative transplantation from related, haploi-
dentical donors resulting from a modified regimen of
posttransplant immunosuppression.
PATIENTS AND METHODS
Patients
Sixty-eight consecutive patients were accrued to 2
similar clinical trials, J9966 at Johns Hopkins and 1667
at the Fred Hutchinson Cancer Research Center. The
protocols were open between 1999 and 2006. Eligible
patients were 0.5-70 years of age with high-risk hema-
tologic malignancies or paroxysmal nocturnal hemo-
globinuria (PNH) for whom standard allogeneic
(HLA-matched, related, or unrelated) or autologousBMTwas unavailable or inappropriate. Eligible hema-
tologic malignancies included interferon- or imatinib-
refractory chronic myelogenous leukemia (CML) in
first chronic phase, CML in second chronic phase,
poor-risk acute leukemia in first complete remission,
acute leukemia beyond the first complete remission,
advanced myelodysplastic syndrome (MDS), and lym-
phoma or multiple myeloma (MM) in resistant relapse
(not responsive to conventional salvage therapy prior
to transplantation) or in relapse after autologous trans-
plantation. Poor-risk characteristics of acute leukemia
in first remission included white blood cell count
.100,000/mL at diagnosis, mixed lineage, delayed re-
sponse to induction chemotherapy, or unfavorable cy-
togenetics [22], including 3 or more chromosomal
abnormalities, Philadelphia chromosome, 27, t(6;9),
t(6;11), isolated trisomy 8, inv(3) or t(3;3), or
t(11;19)(q23;p13.1). Patients were ineligible for the
protocols if they were pregnant, HIV-seropositive,
had active, serious infections, CNS disease refractory
to intrathecal chemotherapy or radiation, Karnofsky
performance status\60, or organ dysfunction defined
by a left ventricular ejection fraction (LVEF)\35%,
DLCO\35%, or total bilirubin .3 mg/dL. The re-
spective protocols received approval by the institu-
tional review boards (IRBs) of the Johns Hopkins
Medical Institutions or the Fred Hutchinson Cancer
Research Center. All patients signed consent forms ap-
proved by the respective IRBs.
HLATyping
HLA phenotyping was performed by the same
methods and similar protocols at both institutions.
Briefly, typing prior to alloBMT was performed using
2 different molecular test methods. Samples were PCR
amplified with HLA locus-specific primers. Amplified
samples were hybridized to panels of sequence specific
oligonucleotide probes (SSOP) bound to plastic mi-
crospheres with a single tube hybridization for each
HLA locus for each sample. The positive and negative
probe reactions were captured by a Luminex Flow
Analyzer and submitted to an HLA analysis program
(One Lambda LabType) loaded with a library of the
expected hybridization patterns of the known HLA
alleles. High-resolution HLA typing to confirm allele
level matchingwas performed by directDNA sequenc-
ing of HLA locus-specific PCR amplified DNA, using
dye terminator chemistry, with analysis on an ABI
3130xl Genetic Analyzer and Assign (Conexio Geno-
mics, Australia) HLA sequencing analysis software.
Potential family members were initially typed at the
HLA-A, HLA-B, and HLA-DRB1 loci at an interme-
diate resolution level. Family members selected as
donors were then further typed at the HLA-C locus
at an intermediate resolution level. DRB1 and DQB1
alleles were typed at a high-resolution level. As needed,
Nonmyeloablative, HLA-Haploidentical BMT with post-BMT Cyclophosphamide 643recipients and potential donors were typed at a high-
resolution level for HLA-Cw alleles. Haplotypes
were determined based on family studies whenever
possible.
Conditioning Regimen and Postgrafting
Immunosuppression (Figure 1)
All patients were intended to be treated as outpa-
tients. Transplantation conditioning was modified
from the regimen developed by Storb and colleagues
[23], and consisted of Cy 14.5 mg/kg/day i.v. on days
26 and 25, fludarabine 30 mg/m2/day i.v. on days
26 to 22, and 200 cGy of TBI on day21 as reported
previously [21]. On day 0, patients received donor
marrow, which was obtained in a targeted collection
of 4  108 nucleated cells/kg recipient weight and de-
pleted of red blood cells by processing on a Gambro
Spectra apheresis instrument. On day 3 (28 patients
in Seattle) or on days 3 and 4 (40 patients in Baltimore),
50 mg/kg Cy was administered over 90 min together
with Mesna (80% dose of Cy in 4 divided doses over
8 hours) by i.v. infusion. Pharmacologic prophylaxis
of GVHDwith tacrolimus and mycophenolate mofetil
(MMF) was not initiated until the day following com-
pletion of posttransplantation Cy to avoid blocking
Cy-induced tolerance [24]. All patients received tacro-
limus (Prograf; Astellas, Deerfield, IL), which was
initiated at a dose of 1mg i.v.. daily, adjusted to achieve
a therapeutic level of 5-15 ng/mL, and then converted
to oral form until discontinuation. If there was no ac-
tive GVHD, tacrolimus was tapered off by day 180.
All patients received MMF (Cellcept, Roche Labora-
tories, Nutley, NJ) until day 35 at a dose of 15 mg/kg
orally 3 times daily with a maximum daily dose of 3 g.
Patients received filgrastim (Neupogen, Amgen,
Thousand Oaks, CA), 5 mg/kg/day by subcutaneous
injection starting on day 4 and continuing until recov-
ery of neutrophils to .1000/mL for 3 days.
Supportive Care
Antimicrobial prophylaxis was administered ac-
cording to the practice guidelines of the respective in-
stitutions and included antibiotics for prophylaxis of
Pneumocystis carinii, Candida albicans, and herpes zos-
ter/simplex. Standard broad-spectrum bacterial
Figure 1. Nonmyeloablative haploidentical BMT conditioning and
postgrafting immunosuppresive regimen.antibiotic prophylaxis with a third-generation cepha-
losporin or quinolone was commonly given to patients
who became neutropenic. All blood products except
for the allograft were irradiated with 25 Gy before
transfusion. The thresholds of RBC and platelet
transfusions were hematocrit\26% or platelet count
\ 10,000/mL. Cytomegalovirus (CMV)-seronegative
patients were given transfusions fromCMV-seronega-
tive donors, or leuko-reduced blood products if CMV-
negative products were unavailable. Patients were
monitored for CMV reactivation by weekly measure-
ment of CMV pp65 in mononuclear cell smears by im-
munofluorescent staining or CMV copy number by
PCR of serum until day 100. Preemptive therapy
with ganciclovir (5 mg/kg i.v. twice daily) was initiated
when$1 CMV antigen-positive cell or$600 copies of
CMV/mL of serum ($100 copies/mL if the patient
was receiving $1 mg/kg steroids) were detected. The
ganciclovir dose was reduced to 5 mg/kg/day after
the viral load began to decline andwas discontinued af-
ter 2 negative surveillance tests. Alternatively, foscar-
net was used at 90 mg/kg twice daily for induction
and then changed to once daily for maintenance.
Chimerism Analyses
At monthly intervals, nucleated cells were isolated
from themarrow or peripheral blood, or T cells (CD3-
positive) and granulocytes (CD33-positive) were
sorted from peripheral blood by flow cytometry. Per-
centages of donor-host chimerism for recipients of
sex-mismatched BMT were determined by fluorescein
in situ hybridization (FISH) [25] using probes for X-
and Y-chromosomes. For recipients of sex-matched
BMT, chimerism was based on restriction fragment
length polymorphisms [26] or PCR analysis of variable
nucleotide tandem repeats [27] unique to donors or re-
cipients [28].
GVHD Grading and Therapy
Acute GVHD (aGVHD) was graded according to
the Keystone Criteria [29]. Chronic GVHD (cGVHD)
was graded according to standard guidelines [30].
First-line therapy of clinically significant aGVHD
consisted of methylprednisolone 1-2.5 mg/kg/day i.v.
plus full-dose tacrolimus or full-dose tacrolimus plus
resumption of MMF.
Study End Points
Patient outcomes are reported as of April 3, 2007.
The major study end points were sustained donor
engraftment, incidence and severity of GVHD, and
nonrelapse mortality (NRM). Successful donor en-
graftment was defined as donor chimerism $50% on
day 60 and stable or improved thereafter. Graft fail-
ure was defined as the inability to detect or loss of de-
tection of $5% donor cells after transplantation, not
644 L. Luznik et al.because of progressive hematologic malignancy. Pa-
tients were considered to have died of NRM if
there was no evidence of disease relapse or progres-
sion before death. Time to recovery of neutrophils
was defined as the interval between transplantation
and the first of 3 consecutive days with an absolute
neutrophil count (ANC) .500/mL. Platelet recovery
was defined as the time interval between transplan-
tation and the first day of a platelet count .20,000/
mL without a platelet transfusion in the preceding
7 days.
Statistical Methods
Probabilities of OS and EFS were estimated using
the Kaplan-Meier method [31]. Probabilities of
aGVHD and cGVHD, relapse, and NRM were sum-
marized using cumulative incidence estimates [32].
Death without engraftment was considered a compet-
ing risk for engraftment; death without relapse was
a competing risk for relapse; relapse was a competing
risk for NRM; graft failure, relapse, or death without
GVHD were considered competing risks for GVHD.
The hazard of failure for each of these endpoints was
compared using Cox regression [33].
Table 1. Patient Characteristics
No. Patients 68
Median age, years (range) 46 (1-71)
Sex: No. (%)
Male 42 (62%)
Female 26 (38%)
Ethnicity: No. (%)
White 51 (75%)
African American 12 (18%)
Asian 2 ( 3%)
Hispanic 2 ( 3%)
Native American 1 ( 1%)
Diagnosis (No.)
AML 27 (40%)
CR1/CR.1/Not in CR 12/13/2
ALL 4 ( 6%)
CR1/CR.1/Not in CR 2/1/1
MDS 1 ( 1%)
CML/CMML 6 ( 9%)
CLL 3 ( 4%)
HL 13 (19%)
NHL 10 (15%)
MM/plasmacytoma 3 ( 4%)
PNH 1 ( 1%)
No. prior treatment regimens (range) 4 (0-10)
No. sensitive to prior treatment (%)* 49 (77%)
No. prior autologous transplant (%) 21 (31%)
AML indicates acute myelogenous leukemia; ALL, acute lympho-
cytic leukemia; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; CMML, chronicmyelomonocytic leuke-
mia; CLL, chronic lymphocytic leukemia; HL, Hodgkin lym-
phoma; NHL, non-Hodgkin lymphoma; MM, multiple
myeloma; PNH, paroxysmal nocturnal hemoglobinuria.
*Not available for 4 patients.RESULTS
Patient and Graft Characteristics
Characteristics of the patient population are listed
in Table 1. All study subjects had poor risk hemato-
logic malignancies, as defined in the Materials and
Methods, except for 1 patient with PNH. Twenty-
one patients (31%) had failed at least 1 autologous
stem cell transplantation (SCT), including 12 of 13 pa-
tients with Hodgkin lymphoma (HL), 4 of 10 patients
with non-Hodgkin lymphoma (NHL), 3 of 27 patients
with acute myelogenous leukemia (AML), and 1 pa-
tient each with chronic lymphocytic leukemia (CLL)
and MM. Twenty-five percent of patients were from
ethnic minority groups.
Characteristics of the donors and the grafts are
listed in Table 2. For the entire group, about half (33
of 68) of the donors were siblings of patients, and about
a quarter each of the donors were either parents or chil-
dren of patients (19 of 68 and 16 of 68, respectively).
The numbers of HLA allele mismatches in the host-
versus-graft (HVG) or graft-versus-host (GVH) direc-
tions are listed.Donors differed from their recipients at
a median of 4HLA loci in both theHVG andGVHdi-
rections. Greater than 70% of donor-recipient pairs
were mismatched for at least 4 HLA loci.
Engraftment and Chimerism
The median time to neutrophil recovery
(Figure 2A) was 15 days, and the median time to plate-
let recovery (Figure 2B) was 24 days.
Graft rejection occurred in 9 of 66 evaluable pa-
tients (13%). All but 1 patient with graft failure expe-
rienced recovery of autologous hematopoiesis with
Table 2. Donor and Graft Characteristics
Median age, years (range) 44 (21-69)
Sex: No. (%)
Male 30 (44%)
Female 38 (56%)
Relationship: No. (%)
Parent 19 (28%)
Sibling 33 (49%)
Child 16 (24%)
CD31 cells/kg  10-7
Mean (SD) 4.2 (1.5)
CD341 cells/kg  10-6
Mean (SD) 4.8 (2.2)
Infused MNC/kg  10-8
Mean (SD) 1.6 (0.5)
HLA mismatches: No. (%) HvG direction GvH direction
0 1 (1%) 1 (1%)
1 1 (1%) 0 (0%)
2 5 (7%) 4 (6%)
3 12 (18%) 14 (21%)
4 18 (27%) 24 (35%)
5 31 (46%) 25 (37%)
Median (range) 4 (0-5) 4 (0-5)
Nonmyeloablative, HLA-Haploidentical BMT with post-BMT Cyclophosphamide 645Figure 2. Engraftment and chimerism. Cumulative incidence of (A) neutrophil and (B) platelet engraftment. Dashed line represents death with-
out engraftment (competing risk). (C) Percentage of donor chimerism at days 28-30 and 56-60. In Seattle, donor chimerism was analyzed from
the CD31 and CD331 fractions of peripheral blood, whereas in Baltimore donor chimerism was analyzed from whole peripheral blood or bone
marrow. Bone marrow samples were not obtained from all evaluable patients.median times to neutrophil and platelet engraftment of
15 days (range: 11-42 days) and 28 days (range: 0-395
days), respectively.
Achievement of full donor chimerism was rapid
after transplantation fromHLA-haploidentical donors
(Figure 2C). Analysis of peripheral blood that was ei-
ther (1) unfractionated or (2) separated by cell sorting
into T cell (CD3-positive) or granulocyte (CD33-
positive) fractions showed that with few exceptions,
donor chimerism in patients with sustained engraft-
ment was virtually complete (.95%) by 2months after
transplantation.
Hospitalizations, Transfusions, and Infections
All patients received their initial treatment in the
outpatient department and were discharged to their re-
ferring oncologist between 60 and 90 days after trans-
plantation, unless complications requiring admission
to the hospital supervened. The median number of
hospitalizations prior to day 60 was 1 (range: 0-4),
and the median length of stay was 4 days (range:0-66). Neutropenic fever accounted for 51% of the
admissions, nonneutropenic infections accounted for
22%, aGVHD accounted for 9%, and other causes
were the reason for the remaining 19% of admissions.
A total of 22 patients (32%) did not require hospitali-
zation within the first 60 days of transplantation.
The median number of red blood cell transfusions
per patient was 6 (range: 0-34), and the median num-
ber of times patients received platelet transfusions
was 4 (range: 0-44). Two and 5 patients, respectively,
did not receive red blood cell or platelet transfusions.
Patients who are seropositive for CMV are known
to be at high-risk for reactivating CMV after trans-
plantation, regardless of the serologic status of the
donor [34]. In this study, CMV reactivation was ob-
served in 17 of 45 (38%) high-risk patients with a me-
dian time to reactivation of 34 days (Table 3).
aGVHD was present in 7 patients on or about the
time of CMV reactivation. There were no cases of
CMV pneumonia and there was no CMV-associated
mortality.
646 L. Luznik et al.Despite effective antifungal prophylaxis, invasive
mold infections, especially Aspergillus, remain an im-
portant problem after alloBMT [35]. However, with
the advent of antimold agents such as voriconazole,
survival of patients with invasive mold infections has
improved significantly [36]. Proved or probable inva-
sive mold infections posttransplant, all caused by
Aspergillus sp, were observed in 5 of 68 (7%) patients.
Two patients died from Aspergillus infection: 1 while
persistently neutropenic following graft failure, and 1
with fungal sinusitis.
aGVHD and cGVHD
The probabilities of grades II-IV and III-IV
aGVHD by day 200 were 34% and 6%, respectively
(Figure 3A). There was no statistically significant dif-
ference in the probability of aGVHD between patients
who received 1 versus 2 doses of posttransplantation
Cy (data not shown). However, Figure 3B shows that
the incidence of extensive cGVHD at 1 year in the
group of patients who received 2 doses of posttrans-
plantation Cy (5%) was suggestively lower than the in-
cidence of extensive cGVHD in the group of patients
who received 1 dose of posttransplantation Cy (25%;
hazard ratio [HR] 0.21; 95% confidence interval [CI]
0.04-1.01; P 5 .05).
NRM and Relapse
The probabilities ofNRM at 100 days and at 1 year
after transplantation were 4% and 15%, respectively,
and the probabilities of relapse at 1 and 2 years after
Table 3. CMV Reactivation and Invasive Mold Infection
No. of patients at high-risk for CMV reactivation 45
No. of high-risk patients with CMV reactivation (%) 17 (38%)
No. of high-risk patients with CMV disease 0
Median days to onset (range) 34 (17-80)
No. of patients with invasive mold infection (%) 5 (7%)transplantation were 51% and 58%, respectively
(Figure 4A). There was no statistically significant ef-
fect of the dose of posttransplantation Cy on either
NRM or relapse (data not shown). Patients with lym-
phoid malignancies had a significantly lower risk of
relapse than patients with myeloid malignancies (HR
0.54, 95% CI 0.30-0.97, P 5 .04).
OS and EFS
At amedian follow-up among survivors of 745 days
(range: 112-1483 days), the actuarial OS at 1 and at 2
years was 46% and 36%, respectively (Figure 4B).
The actuarial EFS at 1 and at 2 years was 34% and
26%, respectively (Figure 4B). OS and EFS were not
statistically significantly different between groups
(data not shown). However, compared to patients
with myelogenous malignancies, patients with lym-
phoid malignancies had a significantly improved
EFS (HR 5 0.50; 95% CI 0.29-0.87; P 5 .02)
(Figure 4C).
Table 4 lists the causes of death among
transplanted patients. Of 42 deaths, 31 occurred in
patients with relapsed or progressive disease. GVHD
accounted for 2 deaths (3%). Only 4 patients died of
infection without GVHD or disease progression (6%).
DISCUSSION
The current report builds upon our initial experi-
ence in the use of high-dose, posttransplantation Cy
for the prevention of graft rejection and aGVHD after
nonmyeloablative conditioning and HLA-haploiden-
tical bone marrow transplantation for advanced hema-
tologic malignancies [21]. Several conclusions may be
drawn. First and foremost, posttransplantation immu-
nosuppression with high-dose Cy, tacrolimus, and
thrice daily MMF was associated with an acceptably
low incidence of fatal graft rejection, severe aGVHD,
and extensive cGVHD, while allowing promptFigure 3. Cumulative incidence of aGVHD and cGVHD. (A) Cumulative incidence of aGVHD grades II-IV and III-IV. (B) Cumulative inci-
dence of extensive cGVHD for patients who received 1 (Seattle) versus 2 (Baltimore) doses of posttransplant Cy.
Nonmyeloablative, HLA-Haploidentical BMT with post-BMT Cyclophosphamide 647Figure 4.Outcomes among nonmyeloablative haploidentical BMT recipients. (A) Cumulative incidence of NRM and relapse. (B) OS and EFS.
(C) EFS, according to disease category (myeloid versus lymphoid).engraftment. The incidence of GVHD in our study is
similar to that reported with reduced intensity HLA-
matched sibling and unrelated donor transplantation
[37-40]. Second, in addition to control of HLA-
haploidentical alloreactivity, there was a suggestion
of effective clinical immune reconstitution as demon-
strated by the low incidence of severe opportunistic
infections. Third, relapse was the major cause of
treatment failure in this population of patients with
poor-risk hematologic malignancies. Finally, the
transplantation regimen is truly nonmyeloablative, as
autologous hematopoiesis recovered in 8 of 9 patients
who rejected their grafts.
An extensive body of preclinical literature supports
the hypothesis that Cy is more effective at suppressing
HVG reactions when given after rather than before
allogeneic solid organ or stem cell transplantation
[17,19,20,41-43]. Posttransplantation Cy was also
found to reduce the incidence and severity of GVHD
following alloBMT in rodents [20,44,45], but not in
a canine model [46]. However, a randomized clinical
trial demonstrated that a lower dose of Cy (7.5 mg/
kg i.v. on days 1, 3, 5, 7, and 9 and then weekly there-
after) was inferior to cyclosporine A in the prophylaxis
of aGVHD after HLA-matched sibling alloBMT [47].
Subsequent studies in the mouse demonstrated that
tolerance to minor histocompatibility antigens could
be induced only if a single dose of $150 mg/kg Cy
was given precisely between 48 and 72 hours after allo-
antigen exposure; tolerance was not induced if the
same dose of Cy was given 24 or 96 hours after trans-
plantation [48]. Thus, in the early clinical trial of post-
transplantation Cy [47], the drug may have been given
at the wrong time or at too low a dose to be maximally
effective at suppressing GVHD. The selection of
a low, intermittent dose of Cy in that trial was moti-
vated by concerns that higher doses of the drug might
kill or impair donor stem cells, leading to graft failure
or delayed engraftment. However, lympho-hemato-
poietic stem cells are relatively quiescent [49] andexpress high levels of aldehyde dehydrogenase, which
likely confer cellular resistance to cyclophosphamide
[50]. These findings may explain why high dose Cy is
not marrow ablative and provided a rationale for its
use in this study and our previous study [21].
The dose, timing, and sequence of administering
Cy, tacrolimus, and MMF were selected based upon
2 lessons learned from the mouse studies. First,
a high dose of Cy must be given in a narrow time win-
dow [48]. Therefore, we gave Cy 50mg/kg i.v. on day 3
or on days 3 and 4 after transplantation. Second, be-
cause cyclosporine A administration blocks Cy-in-
duced tolerance in the mouse [24], initiation of both
tacrolimus and MMF was delayed until after the last
dose of posttransplantation Cy. The exquisite timing
of Cy-induced tolerance and its sensitivity to blockade
by calcineurin inhibitors suggest that the drug induces
tolerance only if the target population of T cells has
been recently and synchronously activated. These
stringent requirements for Cy-induced tolerance may
exempt populations of T cells that are resting, that
have been activated but not recently, or that have
been activated recently but not in synchrony. Thus,
Cy-induced tolerance may afford the opportunity to
selectively target alloreactive T cells while sparing im-
munity to infection. In this regard, we recently re-
ported that 50 mg/kg of Cy on days 3 and 4 after
myeloablative transplantation using HLA-matched
Table 4. Causes of Death
Cause of Death No. (%)
Relapse 31 (46%)
GVHD 2 ( 3%)
Infection 4 ( 6%)
CNS hemorrhage 2 ( 3%)
Secondary AML* 1 ( 1%)
Unknown 2 ( 3%)
AML indicates acute myelogeneous leukemia; GVHD, graft-versus-
hose disease; CNS, central nervous system.
*Recipient origin.
648 L. Luznik et al.sibling or unrelated donors was effective as a single
agent for GVHD prophylaxis without the addition of
a calcineurin inhibitor [51].
In this report, modifications were made to our
original protocol [21] in an attempt to reduce the rates
of graft rejection andGVHD reported previously. One
modification was to increase the dose of posttransplant
Cy in the group of patients transplanted in Baltimore.
The secondmodification was to increase the frequency
of dosing of MMF in both groups to achieve a higher
steady-state concentration, which has been shown to
reduce the rate of rejection in nonmyeloablative trans-
plants from HLA-matched, unrelated donors [52].
The effect of increasing the dose of posttransplant
Cy was to decrease significantly the cumulative inci-
dence of severe cGVHD, a major cause of posttrans-
plant morbidity. However, we cannot rule out the
possibility of a center effect contributing to this differ-
ence. Increasing the dose of posttransplant Cy did not
affect other transplant outcomes significantly. Thus,
thrice daily MMF and 2 doses of posttransplant Cy
appear to be an improved regimen of posttransplant
immunosuppression in our nonmyeloablative trans-
plant protocol using haploidentical donors.
The ability to effectively utilize haploidentical
family members as donors potentially provides rapid
access to allogeneic BMT for virtually all patients in
need of one. However, HLA-haploidentical allogeneic
transplantation has generally been unsuccessful be-
cause of unacceptably high rates of severe GVHD
and opportunistic infections [53,54]. In most studies,
depletion of host and donor T cells in vivo was accom-
plished using polycolonal or monoclonal antibodies
(mAb) specific for lymphocytes. Relatively high rates
of relapse, severe GVHD, and NRM, and low rates
of donor chimerism were observed by Spitzer et al.
[53,54]. Improved engraftment and reduced rates of
aGVHD and cGVHD were observed in the study of
Rizzieri et al. [55], but NRM was 31% mostly because
of infection. In our patients, mortality from infection
was low (\5%). Notably, CMV and invasive mold
infection, which are currently the principal causes of
infectious deaths after myeloablative or nonmyeloabla-
tive BMT, accounted for only 2 deaths on this study. In
contrast, mortality from CMV disease was 14% in a re-
cent study of nonmyeloablative transplantation using
HLA-haploidentical donors [55]. The incidence of in-
vasive mold infections in our patients (7%) also was
lower than expected. Fukuda et al. [56] reported an
incidence of 15% invasive mold infections in nonmye-
loablative transplants from HLA-matched related or
unrelated donors with a mortality rate of 56%. The
low incidence of infection in this study is encouraging
and warrants further investigation.
Certainly one reason for the high risk of relapse in
this study was that eligibility for this trial was mostly
restricted to patients with poor-risk hematologicmalignancies, almost a third of whom had failed prior
autologous transplants. Alternatively, it is possible that
the GVL effect may have been diminished to some ex-
tent by the Cy-mediated deletion or inactivation of tu-
mor-specific T cells. Some patients may have relapsed
or progressed before a GVT effect of transplantation
could manifest itself. Another possible explanation
for the high rate of relapse seen in this trial and other
trials of nonmyeloablative conditioning may be that
the transplantation conditioning was not intense
enough to achieve sufficient tumor cytoreduction or
to augment a GVH reaction through epithelial tissue
damage. Further study is clearly required to determine
why patients continue to relapse despite acquisition of
full donor hematopoietic chimerism.
For adult hematologic malignancies patients who
lack suitably matched related or unrelated donors, en-
couraging outcomes have also been obtained with
transplantation of HLA-haploidentical related stem
cells after myeloablative conditioning [10,57] or with
transplantation of 1 or 2 umbilical cord blood units
after either myeloablative [58-60] or reduced intensity
conditioning (RIC) [61-64]. Both HLA-haploidentical
related and umbilical cord unrelated grafts can be
obtained rapidly for .90% of patients lacking an
HLA-matched donor. Therefore, the choice between
these graft sources and the intensity of conditioning
must balance other considerations, including the pa-
tient’s age, weight, medical condition, the biologic
characteristics of the cancer being treated, and the
relative quality and compatibility of the graft. Care-
fully controlled clinical trials will ultimately be re-
quired to determine the best graft source for adult
patients requiring alternative donor hematopoietic
stem cell transplantation.
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